Novel systemically active galanin receptor 2 ligands in depression-like behavior

Area of Science:

• Neuroscience
• Pharmacology
• Molecular Biology

Background:

• Neuropeptide galanin and its receptors (GalR1-GalR3) are implicated in physiological and disease processes.
• Previous research suggests GalR2 activation may reduce depression-like behaviors.
• A lack of in vivo subtype-specific ligands has limited research into galanin's role in depression.

Purpose of the Study:

• To develop novel, systemically active galanin analogs with enhanced brain penetration for in vivo studies.
• To investigate the antidepressant-like potential of these novel analogs, particularly targeting GalR2.
• To identify potential new pharmaceutical interventions for depression.

Main Methods:

• Synthesis of novel galanin analogs with modified backbones for increased brain levels after intravenous injection.
• Evaluation of antidepressant-like effects in mouse models: forced swim test and tail suspension test.
• Pharmacological characterization including blockade with a galanin receptor antagonist (M35) and testing in GalR2 knockout (GalR2KO) animals.

Main Results:

• Several synthesized galanin analogs demonstrated antidepressant-like effects in mice at low doses (< 0.5 mg/kg), comparable to imipramine.
• The specific analog J18 showed efficacy in both depression models.
• J18's antidepressant-like effect was blocked by M35 and abolished in GalR2KO mice, indicating GalR2-mediated action in the brain.

Conclusions:

• Systemically administered galanin analog J18 exerts antidepressant-like effects through the activation of GalR2 in the brain.
• The novel galanin analogs exhibit potential as drug leads for depression.
• These findings support galanin receptor modulation as a viable pharmaceutical strategy for treating depression.